Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C

Pentraxin 3 (PTX3) plays a pathogenic role in experimental models of chronic liver injury and contributes to the progression of fibrosis. The detection of advanced fibrosis (METAVIR F≥3) is important to identify patients who are in urgent need of antiviral treatments versus those whose treatment cou...

Full description

Bibliographic Details
Main Authors: Joanna Gorka-Dynysiewicz, Monika Pazgan-Simon, Jolanta Zuwala-Jagiello
Format: Article
Language:English
Published: Hindawi Limited 2019-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2019/2639248
id doaj-e8800acdb6804a41aa2d448a177a8f42
record_format Article
spelling doaj-e8800acdb6804a41aa2d448a177a8f422020-11-24T21:50:39ZengHindawi LimitedBioMed Research International2314-61332314-61412019-01-01201910.1155/2019/26392482639248Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis CJoanna Gorka-Dynysiewicz0Monika Pazgan-Simon1Jolanta Zuwala-Jagiello2Department of Pharmaceutical Biochemistry, Wroclaw Medical University, PolandDepartment of Infectious Diseases and Hepatology, Wroclaw Medical University, PolandDepartment of Pharmaceutical Biochemistry, Wroclaw Medical University, PolandPentraxin 3 (PTX3) plays a pathogenic role in experimental models of chronic liver injury and contributes to the progression of fibrosis. The detection of advanced fibrosis (METAVIR F≥3) is important to identify patients who are in urgent need of antiviral treatments versus those whose treatment could be deferred (F≥2). The aim was to assess the diagnostic value of PTX3 as a potential biomarker for clinically significant and advanced fibrosis. PTX3 associations with biochemical and histological parameters of inflammatory activity and fibrosis were investigated in 138 patients with chronic viral hepatitis C (HCV) before antiviral treatment. METAVIR histological scores of activity and fibrosis were obtained. PTX3 was measured by enzyme-linked immunosorbent assay. The diagnostic accuracy of serum PTX3 levels was compared to that of other fibrosis markers, including transforming growth factor‐β1 (TGF-β1), hyaluronic acid (HA), aspartate transaminase to platelet ratio index (APRI), fibrosis score based on four factors (FIB4), gamma-glutamyltranspeptidase to platelet ratio (GPR), and the liver stiffness measurement (LSM) by transient elastography (FibroScan®). In HCV patients the PTX3 level increased in parallel with the METAVIR histological score of activity, being independently associated with the METAVIR fibrosis score (P < 0.001). Using the receiver operating characteristics analysis, the best marker for detecting F≥2 and F≥3 was PTX3 with AUC = 0.802 and AUC = 0.867, respectively. The area under the curve of PTX3 for predicting significant fibrosis (F≥2) was significantly greater than those for the GPR ratio (AUC = 0.648) and FIB-4 score (AUC = 0.770) and similar to that for APRI index (AUC = 0.831). PTX3 provided clinically relevant diagnostic accuracy as a single marker of significant fibrosis.http://dx.doi.org/10.1155/2019/2639248
collection DOAJ
language English
format Article
sources DOAJ
author Joanna Gorka-Dynysiewicz
Monika Pazgan-Simon
Jolanta Zuwala-Jagiello
spellingShingle Joanna Gorka-Dynysiewicz
Monika Pazgan-Simon
Jolanta Zuwala-Jagiello
Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C
BioMed Research International
author_facet Joanna Gorka-Dynysiewicz
Monika Pazgan-Simon
Jolanta Zuwala-Jagiello
author_sort Joanna Gorka-Dynysiewicz
title Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C
title_short Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C
title_full Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C
title_fullStr Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C
title_full_unstemmed Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C
title_sort pentraxin 3 detects clinically significant fibrosis in patients with chronic viral hepatitis c
publisher Hindawi Limited
series BioMed Research International
issn 2314-6133
2314-6141
publishDate 2019-01-01
description Pentraxin 3 (PTX3) plays a pathogenic role in experimental models of chronic liver injury and contributes to the progression of fibrosis. The detection of advanced fibrosis (METAVIR F≥3) is important to identify patients who are in urgent need of antiviral treatments versus those whose treatment could be deferred (F≥2). The aim was to assess the diagnostic value of PTX3 as a potential biomarker for clinically significant and advanced fibrosis. PTX3 associations with biochemical and histological parameters of inflammatory activity and fibrosis were investigated in 138 patients with chronic viral hepatitis C (HCV) before antiviral treatment. METAVIR histological scores of activity and fibrosis were obtained. PTX3 was measured by enzyme-linked immunosorbent assay. The diagnostic accuracy of serum PTX3 levels was compared to that of other fibrosis markers, including transforming growth factor‐β1 (TGF-β1), hyaluronic acid (HA), aspartate transaminase to platelet ratio index (APRI), fibrosis score based on four factors (FIB4), gamma-glutamyltranspeptidase to platelet ratio (GPR), and the liver stiffness measurement (LSM) by transient elastography (FibroScan®). In HCV patients the PTX3 level increased in parallel with the METAVIR histological score of activity, being independently associated with the METAVIR fibrosis score (P < 0.001). Using the receiver operating characteristics analysis, the best marker for detecting F≥2 and F≥3 was PTX3 with AUC = 0.802 and AUC = 0.867, respectively. The area under the curve of PTX3 for predicting significant fibrosis (F≥2) was significantly greater than those for the GPR ratio (AUC = 0.648) and FIB-4 score (AUC = 0.770) and similar to that for APRI index (AUC = 0.831). PTX3 provided clinically relevant diagnostic accuracy as a single marker of significant fibrosis.
url http://dx.doi.org/10.1155/2019/2639248
work_keys_str_mv AT joannagorkadynysiewicz pentraxin3detectsclinicallysignificantfibrosisinpatientswithchronicviralhepatitisc
AT monikapazgansimon pentraxin3detectsclinicallysignificantfibrosisinpatientswithchronicviralhepatitisc
AT jolantazuwalajagiello pentraxin3detectsclinicallysignificantfibrosisinpatientswithchronicviralhepatitisc
_version_ 1725882477406322688